Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

SAN DIEGO–(BUSINESS WIRE)–Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.
Click here to view original post